Abstract
Background: Epidermal growth factor receptor (EGFR) mutations are the most clinically actionable oncogenic drivers in Asian patients with non-small-cell lung cancer (NSCLC). The therapeutic landscape has rapidly evolved from single-agent EGFR tyrosine kinase inhibitors (TKIs) to risk-adapted first-line intensi...
R. Meng, Chun-Wei Xu, Wen-Xian Wang et al.· International Open Medical J...· 0 citations
Background Pathological complete response (pCR) and major pathological response (MPR) are early measures of treatment efficacy with prognostic relevance in patients with non-small cell lung cancer (NSCLC) receiving neoadjuvant chemoimmunotherapy. Individual biomarkers such as programmed cell death-ligand 1 (PD-L1) and...
Ao Li, Zi-Hao Mao, Hai-Long Wang et al.· Translational Lung Cancer Re...· 0 citations
In patients with NSCLC, in patients with NSCLC, down-regulation of FUS or up-regulation of CD36 or SYP was associated with progression to LM, highlighting CD36 as a promising therapeutic target to limit the progression of LM.
Shou-Heng Lin, Kai Yin, M. Zheng et al.· Science Translational Medici...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.